Clinical implications of using molecular diagnostics for ovarian cancers

Pathogenesis and the Role of ARID1A Mutation in Endometriosis-related Ovarian Neoplasms

(2012) Daichi Maeda et al.   ADVANCES IN ANATOMIC PATHOLOGY

Ovarian cancer

(2012) Elise C. Kohn et al.   CANCER

BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer

(2012) Rachel N. Grisham et al.   CANCER

53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes

(2012) Kathryn P. Pennington et al.   GYNECOLOGIC ONCOLOGY

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

(2012) Kathryn Alsop et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas

(2012) Michael S Anglesio et al.   JOURNAL OF PATHOLOGY

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

(2012) John Farley et al.   LANCET ONCOLOGY

Reclassification of serous ovarian carcinoma by a 2-tier system

(2011) Diane C. Bodurka et al.   CANCER

Low-grade serous primary peritoneal carcinoma

(2011) Kathleen M. Schmeler et al.   GYNECOLOGIC ONCOLOGY

A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study

(2011) Robert S. Mannel et al.   GYNECOLOGIC ONCOLOGY

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm

(2011) Robert J. Kurman et al.   HUMAN PATHOLOGY

Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer

(2011) Da Yang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma

(2011) Yasushi Yatabe et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations

(2011) Sohei Yamamoto et al.   MODERN PATHOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

(2011) A. G. Patel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

(2011) T. Walsh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas

(2010) Kwong-Kwok Wong et al.   AMERICAN JOURNAL OF PATHOLOGY

Proteomics as a guiding tool for more effective personalized therapy

(2010) J.-m. Lee et al.   ANNALS OF ONCOLOGY

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas

(2010) Martin Köbel et al.   JOURNAL OF PATHOLOGY

Calculator for ovarian carcinoma subtype prediction

(2010) Steve E Kalloger et al.   MODERN PATHOLOGY

ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas

(2010) Kimberly C. Wiegand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer

(2010) Dariush Etemadmoghadam et al.   PLoS One

Ovarian Low-grade and High-grade Serous Carcinoma

(2009) Russell Vang et al.   ADVANCES IN ANATOMIC PATHOLOGY

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

(2009) Jessica N McAlpine et al.   BMC CANCER

Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

(2009) D. Etemadmoghadam et al.   CLINICAL CANCER RESEARCH

High Poly(Adenosine Diphosphate-Ribose) Polymerase Expression and Poor Survival in Advanced-Stage Serous Ovarian Cancer

(2009) Jason C. Barnett et al.   OBSTETRICS AND GYNECOLOGY

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

(2008) Kathleen M. Schmeler et al.   GYNECOLOGIC ONCOLOGY

Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies

(2008) Martin Köbel et al.   PLOS MEDICINE